L-5-Hydroxytryptophan Versus Placebo in Childhood Migraine Prophylaxis: A Double-Blind Crossover Study

L-5HTP was tested versus placebo in a double-blind crossover study of 27 migraine children aged 6–12 years, who recorded their headaches in a headache diary for 1 month. Twenty-one patients subsequently started the trial. The mean daily dose of L-5HTP was 5 mg/kg body weight, and each treatment period with either L-5HTP or placebo lasted 12 weeks. In group A (L-5HTP—placebo; 10 patients) and group B (placebo—L-5HTP; 11 patients) both L-5HTP and placebo led to a significant reduction of the migraine index and frequency of migraine attacks during the 3rd month of each treatment period. However, we found a treatment x period interaction because the efficacy determinants decreased significantly during the first and the second treatment periods in both groups irrespective of the sequence of treatments. No differences were found between L-5HTP (first period of group A) and placebo (first period of group B).

Download Full-text

The Antihypertensive Effect of Verapamil in Twice and Thrice Daily Dose Regimens. A Randomized, Double-Blind, Crossover Trial

Journal of International Medical Research ◽

10.1177/030006058301100311 ◽

1983 ◽

Vol 11 (3) ◽

pp. 190-193 ◽

Cited By ~ 2

Author(s):

B Hedbäck ◽

K Parment

Keyword(s):

Dose Regimen ◽

Crossover Trial ◽

Antihypertensive Effect ◽

Morning Dose ◽

Double Blind ◽

Daily Dose ◽

The Mean ◽

Daily Dose Regimen ◽

Blind Crossover Study ◽

Double Blind Crossover Study

The antihypertensive effect of verapamil 200 mg b.i.d. was compared with that of verapamil 120 mg t.i.d. in a double-blind crossover study in eight out-patients with essential hypertension. The mean supine blood pressure measured before the morning dose was 150/87 mm Hg in patients treated with verapamil 200 mg b.i.d. and 151/87 mm Hg in those treated with verapamil 120 mg t.i.d. The recently reported prolonged half-life and accumulation of verapamil during steady-state conditions explains the lasting antihypertensive effect with the twice-daily dose regimen. Such a twice daily dose regimen is presumed to be more convenient to the patients and thus improve their compliance.

Download Full-text

Cow's Milk Whey Protein Elicits Symptoms of Infantile Colic in Colicky Formula-Fed Infants: A Double-Blind Crossover Study

PEDIATRICS ◽

10.1542/peds.83.2.262 ◽

1989 ◽

Vol 83 (2) ◽

pp. 262-266 ◽

Cited By ~ 3

Author(s):

Lasse Lothe ◽

Tor Lindberg

Keyword(s):

Crossover Study ◽

Whey Protein ◽

Cow’S Milk ◽

Infantile Colic ◽

Double Blind ◽

Milk Whey ◽

Cow's Milk ◽

The Mean ◽

Blind Crossover Study ◽

Double Blind Crossover Study

There are several causes of infantile colic. The aim of this study was to evaluate, under controlled conditions, whether bovine whey proteins can elicit symptoms of infantile colic in colicky formula-fed infants. The mean age for entering the study was 6.4 weeks and the mean age for colic debut was 3.7 weeks. In 24 of 27 infants with severe colic, the symptoms disappeared when they were given a cow's milk-free diet (Nutramigen). These 24 infants were entered into a double-blind crossover study. The infants (receiving cow's milk-free diet) were given the contents of identical capsules with each meal during day 6. The same procedure was repeated on day 10. The capsules contained either whey protein powder (with Nutramigen added) or human albumin powder (with Nutramigen added). Eighteen infants receiving the whey protein-containing capsules reacted with colic, two infants receiving placebo reacted with colic (P< .001), and four infants did not react at all. Crying hours per day for the 24 infants were 5.6 hours for formula-fed infants and 0.7 hour for cow's milk-free diet-fed infants (P< .001). Crying hours per day were 3.2 hours for the infants receiving whey protein capsules and 1.0 hour for those receiving placebo (P< .001). In conclusion, bovine whey protein can elicit symptoms of infantile colic in colicky formula-fed infants.

Download Full-text

Effectiveness ofMentha piperitain the Treatment of Infantile Colic: A Crossover Study

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2012/981352 ◽

2012 ◽

Vol 2012 ◽

pp. 1-4 ◽

Cited By ~ 10

Author(s):

João Guilherme Bezerra Alves ◽

Rita de Cássia Coelho Moraes de Brito ◽

Telma Samila Cavalcanti

Keyword(s):

Crossover Study ◽

Standard Treatment ◽

Mentha Piperita ◽

Infantile Colic ◽

Common Condition ◽

Chi Square ◽

Double Blind ◽

The Mean ◽

Blind Crossover Study ◽

Double Blind Crossover Study

Background. Infantile colic is a distressing and common condition for which there is no proven standard treatment.Objective. To compare the efficacy ofMentha piperitawith simethicone in treatment for infantile colic.Methods. A double-blind crossover study was performed with 30 infants attending IMIP, Recife, Brazil. They were randomized to useMentha piperitaor simethicone in the treatment of infantile colic during 7 days with each drug. Primary outcomes were mother_s opinion about responses to the treatment, number of daily episodes of colic, and time spent crying, measured by a chronometer. Mann-Whitney and chi-square tests were used to compare the results. This study was previously approved by the Ethical Committee in Research at IMIP.Results. At baseline daily episodes of infantile colic was 3.9 (±1.1) and the mean crying time per day was 192 minutes (±51.6). At the end of the study daily episodes of colic fell to 1.6 (±0.6) and the crying duration decreased to 111 (±28) minutes. All mothers reported decrease of frequency and duration of the episodes of infantile colic and there were no differences between responses toMentha piperitaand simethicone.Conclusions. These findings suggest thatMentha piperitamay be used to help control infantile colic. However, these results must be repeated by others studies.

Download Full-text

Short-Term Treatment of Osteoarthritis: A Comparison of Sodium Meclofenamate and Ibuprofen

Journal of International Medical Research ◽

10.1177/030006058201000110 ◽

1982 ◽

Vol 10 (1) ◽

pp. 46-52 ◽

Cited By ~ 12

Author(s):

Marco A Cimmino ◽

Maurizio Cutolo ◽

Elpis Samantà ◽

Silvano Accardo

Keyword(s):

Crossover Study ◽

Treatment Period ◽

Term Treatment ◽

Short Term ◽

Short Term Treatment ◽

Double Blind ◽

Joint Symptoms ◽

Spine Movement ◽

Blind Crossover Study ◽

Double Blind Crossover Study

A double-blind crossover study compared sodium meclofenamate (300 mg daily) and ibuprofen (900 mg daily) in thirty patients with osteoarthritis. Each treatment period was of 3 weeks duration. Both drugs were effective in reducing the severity of joint symptoms and in improving the range of motion, with the exception of spine movement which did not show any changes from the baseline. Tolerance was good.

Download Full-text

Pharmacokinetics and Tolerability of Factor XIII Concentrates Prepared from Human Placenta or Plasma: a Crossover Randomised Study

Thrombosis and Haemostasis ◽

10.1055/s-0038-1649787 ◽

1995 ◽

Vol 74 (02) ◽

pp. 622-625 ◽

Cited By ~ 29

Author(s):

H H Brackmann ◽

R Egbring ◽

A Ferster ◽

P Fondu ◽

J M Girardel ◽

...

Keyword(s):

Factor Xiii ◽

Bleeding Events ◽

Serious Adverse Events ◽

Double Blind ◽

Randomised Study ◽

The Mean ◽

Blind Crossover Study ◽

Double Blind Crossover Study ◽

Fxiii Activity ◽

Observation Period

SummaryThe pharmacokinetics and tolerability of factor XIII (FXIII) from plasma were compared with those of FXIII from placenta in a randomised, double-blind, crossover study involving 13 patients with congenital FXIII deficiency. Both FXIII activity and FXIII antigen were monitored. No difference was seen in the mean half-lives of the two preparations (9.3 days and 9.1 days for plasma and placenta FXIII activity, respectively). Response was similar for both preparations, but was slightly greater for FXIII from plasma.Similar results were found for recovery (65% vs 60%). The area under the data completed by extrapolation was significantly higher for FXIII from plasma. No differences between preparations in terms of efficacy or tolerability were observed. It can be concluded that treatment with FXIII concentrate from plasma is as efficient as with FXIII concentrate from placenta in terms of recovery and half-life. Both preparations were equivalent in terms of safety during the observation period. With the administration of monthly injections of approximately 30 U/kg serious bleeding events were prevented and no other serious adverse events occurred.

Download Full-text

Inhibition of Spontaneous Platelet Aggregation by Sulfinpyrazone

Thrombosis and Haemostasis ◽

10.1055/s-0038-1666900 ◽

1979 ◽

Vol 42 (02) ◽

pp. 621-625 ◽

Cited By ~ 1

Author(s):

G G Nenci ◽

G Agnelli ◽

M Berrettini ◽

P Parise ◽

E Ballatori

Keyword(s):

Platelet Aggregation ◽

Crossover Study ◽

Double Blind ◽

Platelet Aggregability ◽

Initiation Of Therapy ◽

Spontaneous Platelet Aggregation ◽

Blind Crossover Study ◽

Double Blind Crossover Study

SummaryIn a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.

Download Full-text